

Tegaderm CHG IV Securement Dressing for Central Venous and Arterial Catheter Insertion Sites

A decision tree example with probabilistic sensitivity analysis

Andrew J. Sims

2020-05-12

Introduction

This vignette is an example of modelling a decision tree using the `rdecision` package, with probabilistic sensitivity analysis. It is based on the model reported by Jenks *et al* (2016) in which a transparent dressing used to secure vascular catheters (Tegaderm CHG) was compared with a standard dressing.

Two methods of evaluating the decision are presented. The first method constructs a decision tree and evaluates the costs associated with traversing each pathway through it. The second method is a direct calculation and summation of costs, without the need to construct a tree. Point estimates and probabilistic sensitivity analysis are conducted for both methods.

Model variables

Thirteen variables were used in the model. The choice of variables, their distributions and their parameters are taken from table 3 of Jenks *et al* (2016), with the following corrections:

- For variables with lognormal uncertainty, the manufacturer gave values for the mean m and standard deviation s in log space. However, their standard deviations were quoted as negative values. This was an error, but had no effect on their results, because they sampled values of $\exp(m + sz)$, where z is a sample from a standard normal distribution and is symmetrical about 0. For the variables with log normal uncertainty given below, positive standard deviation parameters, with the same absolute value, have been used as hyperparameters of the log normal distributions. Also note that the *median* value on the natural scale of a random variable distributed as $\log N(m, s)$, where μ and σ are the mean and standard deviation on the log scale, is e^μ ; the mean on the natural scale is slightly larger. For example, the hazard ratio for CRBSI with Tegaderm versus standard dressing was modelled as $\log N(-0.911, 0.393)$, which has median 0.402 (the point estimate of the ratio from the literature) and mean 0.434.
- The relative risk for dermatitis was modelled as $\log N(1.482, 0.490)$.
- The point estimate cost of CRBSI was £9900, not £9990, although the parameters (198,50) are quoted correctly.

The 13 model variables were constructed as follows:

```
# clinical variables
r.CRBSI <- NormalModelVariable$new(
  'r.CRBSI', 'Baseline CRBSI rate', '/1000 catheter days', mu=1.48, sigma=0.074
)
hr.CRBSI <- LogNormalModelVariable$new(
  'hr.CRBSI', 'Tegaderm CRBSI HR', 'ratio', p1=-0.911, p2=0.393
```

```

)
r.LSI <- NormalModelVariable$new(
  'r.LSI', 'Baseline LSI rate', '/patient', mu=0.1, sigma=0.01
)
hr.LSI <- LogNormalModelVariable$new(
  'hr.LSI', 'Tegaderm LSI HR', 'ratio', p1=-0.911, p2=0.393
)
r.Dermatitis <- NormalModelVariable$new(
  'r.Dermatitis', 'Baseline dermatitis risk', '/catheter',
  mu=0.0026, sigma=0.00026
)
rr.Dermatitis <- LogNormalModelVariable$new(
  'rr.Dermatitis', 'Tegaderm Dermatitis RR', 'ratio', p1=1.482, p2=0.490
)

# cost variables
c.CRBSI <- GammaModelVariable$new(
  'c.CRBSI', 'CRBSI cost', 'GBP', alpha=198.0, beta=50
)
c.Dermatitis <- GammaModelVariable$new(
  'c.Dermatitis', 'Dermatitis cost', 'GBP', alpha=30, beta=5
)
c.LSI <- GammaModelVariable$new(
  'c.LSI', 'LSI cost', 'GBP', alpha=50, beta=5
)
c.Tegaderm <- ConstModelVariable$new(
  'c.Tegaderm', 'Tegaderm CHG cost', 'GBP', const=6.21
)
c.Standard <- ConstModelVariable$new(
  'c.Standard', 'Standard dressing cost', 'GBP', const=1.34
)
n.cathdays <- NormalModelVariable$new(
  'n.cathdays', 'No. days with catheter', 'days', mu=10, sigma=2
)
n.dressings <- NormalModelVariable$new(
  'n.dressings', 'No. dressings', 'dressings', mu=3, sigma=0.3
)

```

The decision tree approach

The decision problem may be solved by constructing a decision tree comprising decision nodes, chance nodes and leaf nodes. The general approach is to create expressions involving model variables, construct a tree, and then evaluate the decision for the base case and its uncertainty.

Model variable expressions

Variables in the model may be included in the decision tree via mathematical expressions, which involve model variables and are themselves model variables. Forms of expression involving R's numerical functions and multiple model variables are supported, provided they conform to R syntax. The following code creates the model variable expressions to be used as values in the decision tree nodes.

```

# probabilities
p.Dermatitis.S <- ExpressionModelVariable$new(
  'p.Dermatitis.S', 'P(dermatitis|standard dressing)', 'P',
  quote(n.dressings*r.Dermatitis)
)
p.Dermatitis.T <- ExpressionModelVariable$new(
  'p.Dermatitis.T', 'P(dermatitis|Tegaderm)', 'P',
  quote(n.dressings*r.Dermatitis*rr.Dermatitis)
)
r.LSI.T <- ExpressionModelVariable$new(
  'r.LSI.T', 'P(LSI|Tegaderm)', 'P',
  quote(r.LSI*hr.LSI)
)
p.CRBSI.S <- ExpressionModelVariable$new(
  'p.CRBSI.S', 'P(CRBSI|standard dressing)', 'P',
  quote(r.CRBSI*n.cathdays/1000)
)
p.CRBSI.T <- ExpressionModelVariable$new(
  'p.CRBSI.T', 'P(CRBSI|Tegaderm)', 'P',
  quote(r.CRBSI*n.cathdays*hr.CRBSI/1000)
)

# costs
c.S <- ExpressionModelVariable$new(
  'c.S', 'Cost of standard dressing', 'GBP',
  quote(n.dressings*c.Standard)
)
c.T <- ExpressionModelVariable$new(
  'c.T', 'Cost of Tegaderm', 'GBP',
  quote(n.dressings*c.Tegaderm)
)

```

The decision tree

The following code constructs the decision tree, node by node, based on figure 2 of Jenks *et al* (2016). In the formulation used by `rdecision`, each node is a potentially recursive structure which is allowed to have zero or more child nodes; any child nodes must have already been declared before their parent node is declared. This implies that a tree should be constructed from right to left, starting with leaf nodes which have no children (leaf nodes are synonymous with pathways in Briggs' terminology (2006)). The final node to be constructed is the node representing the decision problem.

```

# standard dressing branch
leaf.S.Dermatitis <- LeafNode$new('Dermatitis (Standard Dressing)')
leaf.S.LSI <- LeafNode$new('Local site infection (Standard Dressing)')
leaf.S.CRBSI <- LeafNode$new('CRBSI (Standard Dressing)')
leaf.S.NoComp <- LeafNode$new('No complication (Standard Dressing)')

chance.S <- ChanceNode$new(
  children = list(leaf.S.Dermatitis, leaf.S.LSI, leaf.S.CRBSI, leaf.S.NoComp),
  edgelabels = c('Dermatitis', 'Local site infection', 'CRBSI', 'No complication'),
  costs = list(c.Dermatitis, c.LSI, c.CRBSI, 0),
  p = list(p.Dermatitis.S, r.LSI, p.CRBSI.S, NA)
)

```

```

#> Warning in .subset2(public_bind_env, "initialize")(...): ChanceNode$new:
#> `ptype='MV'` may lead to p values out of range [0,1].

# Tegaderm dressing branch
leaf.T.Dermatitis <- LeafNode$new('Dermatitis (Tegaderm CHG)')
leaf.T.LSI <- LeafNode$new('Local site infection (Tegaderm CHG)')
leaf.T.CRBSI <- LeafNode$new('CRBSI (Tegaderm CHG)')
leaf.T.NoComp <- LeafNode$new('No complication (Tegaderm CHG)')

chance.T <- ChanceNode$new(
  children = list(leaf.T.Dermatitis, leaf.T.LSI, leaf.T.CRBSI, leaf.T.NoComp),
  edgelabels = c('Dermatitis', 'Local site infection', 'CRBSI', 'No complication'),
  costs = list(c.Dermatitis, c.LSI, c.CRBSI, 0),
  p = list(p.Dermatitis.T, r.LSI.T, p.CRBSI.T, NA)
)
#> Warning in .subset2(public_bind_env, "initialize")(...): ChanceNode$new:
#> `ptype='MV'` may lead to p values out of range [0,1].

# decision node
d <- DecisionNode$new(
  children = list(chance.S, chance.T),
  edgelabels = c('Standard', 'Tegaderm'),
  costs = list(c.S, c.T)
)

```

In the manufacturer's model, the uncertainties in the probabilities associated with the polytomous chance nodes were modelled as independent variables. This is not recommended because there is a chance that a particular run of the PSA will yield probabilities that are outside the range [0,1]. Representing the uncertain probabilities with draws from a Dirichlet distribution is preferred. Creating a **ChanceNode** with **ModelVariables** is permitted, but results in a warning being issued.

Summary of the model

The model variables and their operands associated with a node and (optionally) its descendants can be tabulated using the method **tabulateModelVariables**. This returns a data frame describing each variable, its description, units and uncertainty distribution. Variables inheriting from type **ModelVariable** will be included in the tabulation; regular numeric values will not be listed. For extensive models, variables associated with separate branches of a tree can be tabulated separately by calling the method for different head nodes.

The operands of model variables which are expressions of other model variables can be included in the tabulation via the **include.operands** parameter. This is recursive, allowing the complete structure of a model, *i.e.* its model variables and the way in which they are combined, to be tabulated. In the Tegaderm model, the complete structure is as follows:

Description	Label	Distribution
Cost of standard dressing	c.S	n.dressings * c.Standard
Standard dressing cost	c.Standard	Constant
No. dressings	n.dressings	N(3,0.3)
Cost of Tegaderm	c.T	n.dressings * c.Tegaderm
Tegaderm CHG cost	c.Tegaderm	Constant
P(dermatitis standard dressing)	p.Dermatitis.S	n.dressings * r.Dermatitis
Baseline dermatitis risk	r.Dermatitis	N(0.0026,0.00026)
Baseline LSI rate	r.LSI	N(0.1,0.01)

Description	Label	Distribution
No. days with catheter	n.cathdays	N(10,2)
P(CRBSI standard dressing)	p.CRBSI.S	r.CRBSI * n.cathdays/1000
Baseline CRBSI rate	r.CRBSI	N(1.48,0.074)
Dermatitis cost	c.Dermatitis	Ga(30,5)
LSI cost	c.LSI	Ga(50,5)
CRBSI cost	c.CRBSI	Ga(198,50)
P(dermatitis Tegaderm)	p.Dermatitis.T	n.dressings * r.Dermatitis * rr.Dermatitis
Tegaderm Dermatitis RR	rr.Dermatitis	LN1(1.482,0.49)
Tegaderm LSI HR	hr.LSI	LN1(-0.911,0.393)
P(LSI Tegaderm)	r.LSI.T	r.LSI * hr.LSI
Tegaderm CRBSI HR	hr.CRBSI	LN1(-0.911,0.393)
P(CRBSI Tegaderm)	p.CRBSI.T	r.CRBSI * n.cathdays * hr.CRBSI/1000

Point estimates and distributions of model variables

The point estimates, units and distributional properties are obtained from the same call, in the remaining columns. Rows with **Qhat** indicate that the quantiles have been estimated from simulation.

Description	Units	Mean	Q2.5	Q97.5	Qhat
Cost of standard dressing	GBP	4.020	3.251	4.742	*
Standard dressing cost	GBP	1.340	1.340	1.340	
No. dressings	dressings	3.000	2.412	3.588	
Cost of Tegaderm	GBP	18.630	15.084	22.346	*
Tegaderm CHG cost	GBP	6.210	6.210	6.210	
P(dermatitis standard dressing)	P	0.008	0.006	0.010	*
Baseline dermatitis risk	/catheter	0.003	0.002	0.003	
Baseline LSI rate	/patient	0.100	0.080	0.120	
No. days with catheter	days	10.000	6.080	13.920	
P(CRBSI standard dressing)	P	0.015	0.009	0.021	*
Baseline CRBSI rate	/1000 catheter days	1.480	1.335	1.625	
Dermatitis cost	GBP	150.000	101.204	208.244	
LSI cost	GBP	250.000	185.555	323.903	
CRBSI cost	GBP	9900.000	8568.994	11325.687	
P(dermatitis Tegaderm)	P	0.039	0.012	0.085	*
Tegaderm Dermatitis RR	ratio	4.963	1.685	11.500	
Tegaderm LSI HR	ratio	0.434	0.186	0.869	
P(LSI Tegaderm)	P	0.043	0.018	0.098	*
Tegaderm CRBSI HR	ratio	0.434	0.186	0.869	
P(CRBSI Tegaderm)	P	0.006	0.002	0.014	*

Running the model

The following code runs a single model scenario, using the `evaluatePathways` method of a decision node to evaluate each pathway from the decision node. In the model there are eight possible root-to-leaf paths, each of which begins with the decision node and ends with a leaf node. For example, pathway **Dermatitis (Standard Dressing)** involves a traversal of nodes **d**, **chance.S**, and **leaf.S.Dermatitis**. The method `evaluateChoices` is similar, but aggregates the results by choice. The results of the scenario model, using the code from the previous section, yields the following table. This model did not consider utility, and the columns associated with utility are removed.

Choice	Pathway	Probability	Cost	ExpectedCost
Standard	Dermatitis (Standard Dressing)	0.0078	154.02	1.20
Standard	Local site infection (Standard Dressing)	0.1000	254.02	25.40
Standard	CRBSI (Standard Dressing)	0.0148	9904.02	146.58
Standard	No complication (Standard Dressing)	0.8774	4.02	3.53
Tegaderm	Dermatitis (Tegaderm CHG)	0.0387	168.63	6.53
Tegaderm	Local site infection (Tegaderm CHG)	0.0434	268.63	11.67
Tegaderm	CRBSI (Tegaderm CHG)	0.0064	9918.63	63.77
Tegaderm	No complication (Tegaderm CHG)	0.9114	18.63	16.98

Model results

Base case

The total cost for each choice can be calculated from the table above, or by calling `evaluateChoices`, giving a point estimate of the saving of 77.76 GBP. This is close to the sponsor's point estimate of cost saving estimated from their probabilistic sensitivity analysis, 77.26 GBP, reported in Jenks *et al* (2016).

Probabilistic sensitivity analysis

When they are created, each `ModelVariable` returns its expected value when its method `value()` is called. Calling the method `sample()` of a model variable causes it to sample from its uncertainty distribution, and return the sampled value when method `value()` is next called. The same sampled value will be returned until `sample()` is called again. Calling `sample(expected=T)` causes `value()` to return the expected value of the variable.

Probabilistic sensitivity analysis is supported through the use of sampling model variables. In practice, because the model variables enter the model via nodes, the methods `evaluatePathways` and `evaluateChoices` provided by decision nodes provide a convenient interface for sampling from model variables. These methods, called with `expected=FALSE` cause each model variable associated with the decision node and its descendants to be sampled. For further convenience the method `evaluateChoices` permits replicates to be run (parameter `N`), making PSA straightforward. The first few runs of PSA are as follows:

Run	Cost.Tegaderm	Cost.Standard	Difference
1	66.66	190.13	-123.47
2	158.43	238.43	-80.00
3	82.43	221.45	-139.02
4	75.75	144.52	-68.77
5	101.12	218.04	-116.92
6	60.74	130.62	-69.87
7	89.94	221.61	-131.68
8	85.83	161.49	-75.66
9	55.47	93.12	-37.65
10	144.06	182.45	-38.39

From PSA (1000 runs), the mean cost of treatment with Tegaderm was 100.3, the mean cost of treatment with standard dressings was 176.55 and the mean cost saving was -76.25. The 95% confidence interval for cost saving was -141.67 to -5.7; the standard deviation of the cost saving was 33.57. Overall, 97.9% of runs found that Tegaderm was cost saving. These results replicate those reported by the manufacturer (saving of 77.26, 98.5% cases cost saving).

An alternative, tree-free approach

It is possible to solve the decision problem without first constructing a tree, by combining model variables directly. This is, in essence, the approach taken in many decision tree models constructed in Excel.

Components of cost

Each cost component is defined as an expression involving two or more of the 13 model inputs. In contrast to the tree approach, which computed the cost of traversing each pathway, this approach allows the costs of the technology and its comparator to be constructed as sub-totals.

```
# component costs, standard dressing
CHG.S <- ExpressionModelVariable$new(
  'CHG.S', "Cost of standard dressing", "GBP",
  quote(n.dressings*c.Standard)
)
CRBSI.S <- ExpressionModelVariable$new(
  'CRBSI.S', "Cost of CRBSI, standard dressing", "GBP",
  quote(c.CRBSI*r.CRBSI*n.cathdays/1000)
)
LSI.S <- ExpressionModelVariable$new(
  'LSI.S', "Cost of LSI, standard dressing", "GBP",
  quote(c.LSI*r.LSI)
)
Dermatitis.S <- ExpressionModelVariable$new(
  'Dermatitis.S', "Cost of dermatitis, standard dressing", "GBP",
  quote(r.Dermatitis*c.Dermatitis*n.dressings)
)

# component costs, Tegaderm
CHG.T <- ExpressionModelVariable$new(
  'CHG.T', "Cost of Tegaderm", "GBP",
  quote(n.dressings*c.Tegaderm)
)
CRBSI.T <- ExpressionModelVariable$new(
  'CRBSI.T', "Cost of CRBSI, Tegaderm", "GBP",
  quote(c.CRBSI*r.CRBSI*hr.CRBSI*n.cathdays/1000)
)
LSI.T <- ExpressionModelVariable$new(
  'LSI.T', "Cost of LSI, Tegaderm", "GBP",
  quote(c.LSI*r.LSI*hr.LSI)
)
Dermatitis.T <- ExpressionModelVariable$new(
  'Dermatitis.T', "Cost of dermatitis, Tegaderm", "GBP",
  quote(r.Dermatitis*c.Dermatitis*rr.Dermatitis*n.dressings)
)

# per-patient costs
total.T <- ExpressionModelVariable$new(
  'total.T', 'Treatment cost (Tegaderm)', 'GBP',
  quote(CHG.T+CRBSI.T+LSI.T+Dermatitis.T)
)
total.S <- ExpressionModelVariable$new(
```

```

'total.S', 'Treatment cost (Standard)', 'GBP',
quote(CHG.S+CRBSI.S+LSI.S+Dermatitis.S)
)
c.diff <- ExpressionModelVariable$new(
'c.diff', 'Cost difference', 'GBP',
quote(total.T-total.S)
)

```

Base case

The components of cost can be extracted by tabulating the model variables in the cost difference model variable, `c.diff` via method `tabulate`. In this case, only the rows containing component costs are displayed.

Description	Units	Mean	SD	Q2.5	Q97.5	Qhat
Cost difference	GBP	-77.76	32.54	-143.35	-19.00	*
Treatment cost (Tegaderm)	GBP	98.95	32.23	56.89	168.13	*
Cost of Tegaderm	GBP	18.63	1.86	15.04	22.00	*
Cost of CRBSI, Tegaderm	GBP	63.65	29.70	24.41	144.31	*
Cost of LSI, Tegaderm	GBP	10.86	4.91	4.25	22.21	*
Cost of dermatitis, Tegaderm	GBP	5.81	3.33	1.73	13.94	*
Treatment cost (Standard)	GBP	176.71	31.34	119.56	251.32	*
Cost of standard dressing	GBP	4.02	0.40	3.23	4.78	*
Cost of CRBSI, standard dressing	GBP	146.52	33.14	81.94	214.45	*
Cost of LSI, standard dressing	GBP	25.00	4.31	17.32	33.80	*
Cost of dermatitis, standard dressing	GBP	1.17	0.27	0.73	1.75	*

The point estimate of saving is obtained directly from the expectation of the cost difference variable, 77.76. This is identical to the value obtained from the full tree. The table also indicates, by the quantiles of the cost difference, the approximate confidence interval of the saving.

Probabilistic sensitivity analysis

Each model variable provides a method, `r`, to make random draws from its uncertainty distribution. The PSA for the cost difference can therefore be achieved by a single call to this method. From this, the mean cost saving was -79.15, the 95% confidence interval of the saving was -143.18 to -7.34 and 98.2% of runs generated a cost saving. Within fluctuation error this is consistent with the manufacturer's reported saving of 77.26 with 98.5% of runs being cost saving.

A note on correlation of model variables

Of the 13 input variables defined in the tree model, eight appear in both the main branches of the decision tree. If, in PSA, common variables are sampled from their uncertainty distributions once per run, rather than being sampled for each choice within a run, the costs of each arm will be correlated.

In the original Excel model submitted by the manufacturer, the model variables were sampled once per run. The tree model constructed using `rdecision` described in this vignette made the same assumption, and replicated the manufacturer's results. The correlation coefficient between 1000 samples from the cost of treatment with Tegaderm and the cost with standard care was 0.433. This reflects the relatively high degree of correlation between the two choice arms of the model, because of the eight shared model variables.

However, `rdecision` includes the facility to resample the model variables for each choice, within each run, by setting parameter `uncorrelate=TRUE` in method `evaluateChoices` of a decision node. With this option, the equivalent correlation coefficient is 0.004; *i.e.* they are uncorrelated within statistical fluctuation. This does not affect the point estimate, but does alter the distribution of the cost difference, which has standard deviation 42.95 and 95% confidence interval -153.99 to 11.99, with 95% of simulations being cost saving. The confidence interval includes zero, but the percentage of cost saving cases exceeds 95%; with correlation removed, the evidence for a cost saving is therefore marginal, given the input parameters.

Finally, the variance of the cost of treatment with Tegaderm is 31.41^2 , the variance of the cost of treatment with standard care is 31.85^2 and the covariance with correlated model variables is 432.88. Via the relation $Var(X - Y) = Var(X) + Var(Y) - 2Cov(X, Y)$, the variance of the cost difference with correlated model variables is 33.69^2 and with the uncorrelated model variables is 44.73^2 , close to the observed values.

References

- Briggs, Andrew, Karl Claxton, and Mark Sculpher. 2006. *Decision Modelling for Health Economic Evaluation*. Oxford, UK: Oxford University Press.
- Jenks, Michelle, Joyce Craig, William Green, Neil Hewitt, Mick Arber, and Andrew J. Sims. 2016. “Tegaderm CHG IV Securement Dressing for Central Venous and Arterial Catheter Insertion Sites: A NICE Medical Technology Guidance.” *Applied Health Economics and Health Policy*.